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Abstract 2604 − Table 1
CTV D95(Gy) Mean (range)

CTV V100(%) Mean (range)

Plan

4527 (4505-4563)

98.0 (96.1-99.7)

Veriﬁcation 1

4510 (4456-4536)

95.3 (86.7-99.4)

Veriﬁcation 2

4518 (4478-4552)

96.5 (88.6-99.3)

Veriﬁcation 3

4509 (4470-4554)

95.4 (86-99.4)

Veriﬁcation 4

4515 (4455-4542)

96.1 (83.9-98.8)
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Recurrence Risk Stratiﬁcation for Women with FIGO Stage I
Uterine Endometrioid Carcinoma Who Underwent Surgical
Lymph Node Evaluation
A.I. Ghanem,1,2 A. Bhatnagar,3 M. Elshaikh,1 C. Burmeister,4 and
M.A. Elshaikh1; 1Department of Radiation Oncology, Henry Ford Cancer
Institute, Detroit, MI, 2Alexandria Clinical Oncology Department, Alexandria University, Alexandria, Egypt, 3Department of Radiation Oncology,
Henry Ford Cancer Institute, Detroit, MI, 4Department of Public Health Sciences, Henry Ford Cancer Institute, Detroit, MI
Purpose/Objective(s): To estimate the recurrence risk based on the number of prognostic factors in women with FIGO stage I uterine endometrioid
carcinoma (EC) in a large cohort of patients who underwent surgical staging including surgical lymph node evaluation (SLNE) and were managed
with no adjuvant therapy.
Materials/Methods: We queried our in-house prospectively maintained
uterine cancer database for patients with FIGO stage I EC underwent surgical staging including SLNE between 1/1990-12/2020. Patients with synchronous ovarian and breast cancer diagnosis were excluded as well as
those who received adjuvant therapy of any form. Patient’s demographics
and pathologic variables were analyzed. We used multivariate analysis
(MVA) with Stepwise Model Selection to determine risk factors for 5-year
recurrence-free survival (RFS). Study population was then stratiﬁed based
on the number of risk factors identiﬁed (0, 1 or 2). The resultant groups
were compared for RFS, disease-speciﬁc survival (DSS) and overall survival
(OS) using log-rank test and Kaplan-Meier curves. Additionally, independent predictors of DSS and overall OS were estimated.
Results: 706 patients were identiﬁed who met our inclusion criteria with a
median age of 60 years (range, 30-93) and a median follow-up of 120
months. All patients had at least pelvic SLNE with a median number of
examined lymph node (LN) of 8 (range, 1-66): 66 patients (11%) had a sentinel LN sampling and 43% had paraaortic SLNE. 639 patients (91%) were
stage IA and lymphovascular space invasion (LVSI) was detected in 6%
(n=41). Recurrence was diagnosed in 44 patients (6%). Independent predictors of 5-year RFS include age ≥ 60 years (p=0.038), grade 2 vs. 1 (p=0.003),
and grade 3 vs 1 (p<0.001). 5-year RFS for group-0 (age < 60 years and
grade 1) was 98% vs. 92% for group-1 (either: age ≥ 60 years or grade 2/3)
vs 84% for group-2 (both: age ≥ 60 years and grade 2/3), respectively
(p<0.001). 5- year DSS for the three groups was (100% vs 98% vs 95%,
p=0.012) and 5-year OS was (98% vs 90% vs 81%, p<0.001), respectively.
On MVA, stage IB vs IA was deterministic for DSS (p=0.02); whereas age ≥
60 years (p<0.001) and grade 3 vs grade 1 (p=0.004) were predictors for
worse OS.
Conclusion: In patients with stage I endometrioid carcinoma who had surgical staging including SLNE and no adjuvant therapy, only age ≥ 60 years
and high tumor grade were independent predictors of cancer recurrence
and hence can be used to quantify individualized recurrence risk. Surprisingly, LVSI was not an independent prognostic factor in this study cohort
with SLNE.

Author Disclosure: A.I. Ghanem: None. A. Bhatnagar: None. M.
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Bone Marrow Toxicity and Tolerance of Sandwich Therapy
for Advanced-Stage Endometrial Cancer: A SingleInstitution Experience
C. Jalai,1 J. Tang,2 L. Gabor,1 J.M. Jiang,2 K. Lin,1 D. Kuo,1 and K.J. Mehta2;
1
Department of Gynecologic Oncology, Albert Einstein College of Medicine
and Monteﬁore Medical Center, Bronx, NY, 2Department of Radiation
Oncology, Albert Einstein College of Medicine and Monteﬁore Medical Center, Bronx, NY
Purpose/Objective(s): Adjuvant therapy for advanced-stage endometrial
cancer (EC) involve chemotherapy (CT) and/or radiation therapy (RT).
Institutional practices vary regarding the sequencing of these therapies.
While recent trials favored concurrent chemoradiation followed by consolidating CT, there is no randomized comparison of efﬁcacy between ‘sandwich’ (ST) versus concurrent CT. Previous studies show BM dose is
predictive of hematological toxicities (HT) in concurrent chemoradiation.
In this study, we sought to determine whether bone marrow dose contributes to hematological toxicity in ST for treatment of advanced-stage EC.
Materials/Methods: Data for patients who received ST (CT with carboplatin/paclitaxel then 45 Gy external beam radiation therapy [EBRT] with/
without paraaortic [PA] ﬁelds then additional CT) at a single academic
institution for EC cases was abstracted. Full ST was deﬁned as 3 CT cycles,
then RT, followed by a ﬁnal 3 CT cycles. Grade 3 (G3) higher hematologic
toxicities (ANC <1000, Hgb <8.0, platelet count <50,000) were recorded
for each patient based at the time of infusion or radiation therapy. T-test
and Chi-square test were used as appropriate to determine association.
Results: 98 EC patients that underwent ST were included; 66.0% were stage
IIIC. 84% of patients completed full ST, and 26.3% of cases experienced ≥1
treatment delay. Among cycle delays cases, 57.7% had ≥1 G3 hematologic
toxicity: 10 neutropenia, 4 anemia, and 3 thrombocytopenia. HT rate was
49.0%: 34% neutropenia, 13% anemia, 12% thrombocytopenia. Frequency
of cycle delay (31.3% vs. 21.6%) or ST non-completion (13.7% vs. 18.4%)
were not signiﬁcantly associated with HT presence (p>0.05, all). Signiﬁcantly fewer patients who had HT both pre- and post-EBRT completed
post-sandwich CT compared to toxicities occurring at other time intervals
(Table). While patients with ≥2 HT during their treatment received a signiﬁcant larger mean bone marrow radiation dose (69.0 vs 72.5%, p=0.037),
overall dosimetric data were similar regardless of HT timing during treatment. PA boost did display more frequent HT following RT (21.1% vs.
51.7%, p = 0.033) but completed ST at similar rates (63.2% vs 36.8%,
p=0.441). There was a 10% mortality rate; overall survival was similar
despite presence of HT occurrence, or with HT requiring a cycle delay or
cycle non-completion (p>0.05, all cases).
Conclusion: In our study, BM dose does matter in determining HT even in
ST, but does not affect overall treatment completion. The treatment completion rate is comparable to those reported historically for CT only arm.
Low rates of cycle interruption and similar overall survival point to a promising safety and efﬁcacy proﬁle with ST.
Abstract 2606 − Table 1: Table: Comparison of hematologic toxicities
(HT) pre- and post-radiation therapy (RT) based on chemotherapy cycle
characteristics.
Cycle Delay (%)
HT Timing

Pre-RT
Post-RT
Pre+Post-RT

P-value

Cycle Completion (%)

26.3%

94.7%

36.4%

90.9%

27.8%

66.7%

0.832

*0.024
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